Aureus Pharma Announces its Participation in EUR 118 Million Biointelligence R&D Programme

Aureus Pharma, a leading provider of knowledge management solutions to accelerate discovery in the life sciences industry, announces today its participation in a EUR 118.2 million (USD 160 million) project. The project is the Biointelligence R&D programme, designed to promote the use of systemic modeling and simulation tools to exploit biomedical databases to improve research efficiency.

The BioIntelligence R&D programme will be coordinated by Dassault Systèmes, and involve leading life science industry players such as sanofi-aventis, Ipsen, Servier, Pierre Fabre, Bayer Cropscience, as well as public research institutes like Inserm, Inria and Genopole, and SMEs specialised in bioinformatics such as Aureus and Sobios. This programme will account for a total of EUR 118.2 million of eligible expenditure from which EUR 46.3 million will be from OSEO, a public company supporting innovation and growth of SMEs.

BioIntelligence will promote the use of systemic modelling and simulation tools to exploit biomedical databases. This innovative approach, based on the Product Lifecycle Management (PLM) method used by manufacturing industries, will enable life science industries to optimize the research phases of drug development.

Aureus will participate in the development of the Knowledge Management layer of the planned system and build new innovative content in therapeutic areas like oncology, as well as in the area of nuclear receptors, proteases inhibitors and life science semantics. In addition to providing significant funding, this programme will also enable Aureus to evolve its data models to integrate more complex drug and drug candidate properties, biological protocols or regulation of physiological responses. Aureus Pharma expects to receive aids for a total of EUR 3.5 million but further details are not being made public.

"We are excited at the opportunity working with such prestigious partners in the Biointelligence consortium," said Dr Jason Theodosiou, President & CEO of Aureus Pharma. "This programme confirms the key contribution of Aureus' know-how in the development of knowledge-driven information systems in the life science industry. Aureus brings its long term experience in organizing and structuring scientific data into knowledge. This programme will provide Aureus further resources and insight on scientists' specific needs and sustain the development of new innovative products to continue serving our market."

About Aureus Pharma
Aureus Pharma, provides a range of scientific knowledge solutions enabling biopharmaceutical companies to better understand the relationships of biological targets to compounds under evaluation. Aureus experts continuously monitor and organize the most relevant information from the scientific literature, including experimental in vitro and in vivo protocols. This detailed knowledge forms the AurSCOPE(R) database line, focusing on the human body's main therapeutic targets: GPCRs, Kinases, Ion Channels, Proteases and Nuclear Receptors. Additional AurSCOPE(R) databases relate to safety, toxicology, and pharmacokinetics (ADME, hERG). Consolidating all the therapeutic targets, the AurSCOPE(R) Global Pharmacology Space (GPS) provides researchers with the most comprehensive available coverage of the "druggable" genome. Applications include AurQUEST(R), the web-based query tool, DDI Predict(R) for drug-drug interactions, and AurPROFILER(R), the compound profiling visualization tool. Headquartered in Paris, France, Aureus Pharma's information solutions are proven to streamline the discovery process for many of the world's most successful biopharmaceutical companies and prestigious research institutions.